Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: The putative upstream role of SOX2

Thyroid

Volumn 23, Issue 7, 2013, Pages 829-837

  Carina, Valeria ^a   Zito, Giovanni ^a   Pizzolanti, Giuseppe ^a   Richiusa, Pierina ^a   Criscimanna, Angela ^a   Rodolico, Vito ^a   Tomasello, Laura ^a   Pitrone, Maria ^a   Arancio, Walter ^a   Giordano, Carla ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; BREAST CANCER RESISTANCE PROTEIN; CELL MARKER; CISPLATIN; DOXORUBICIN; FORMALDEHYDE; OCTAMER TRANSCRIPTION FACTOR 4; PARAFFIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ANAPLASTIC THYROID CANCER; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER TISSUE; CELL DEATH; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EMBEDDING; EX VIVO STUDY; FLOW CYTOMETRY; FORMALIN FIXED PARAFFIN EMBEDDED; GENE SILENCING; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PLURIPOTENT STEM CELLS; SOXB1 TRANSCRIPTION FACTORS; THYROID NEOPLASMS; UP-REGULATION;

EID: 84881407804     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0372     Document Type: Article

References (44)

1. Gharib H, Papini E, Paschke R 2008 Thyroid nodules: A review of current guidelines, practices, and prospects. Eur J Endocrinol 159:493-505
2. Thomas T, Nowka K, Lan L, Derwahl M 2006 Expression of endoderm stem cell markers: Evidence for the presence of adult stem cells in human thyroid. Thyroid 16:537-544
3. Thomas D, Friedman S, Lin RY 2008 Thyroid stem cells: Lessons from normal development and thyroid cancer. Endocr Relat Cancer 15:51-58
4. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ 2004 Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-6
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF 2003 Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983-3988
6. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB 2003 Identification of a cancer stem cell in human brain tumours. Cancer Res 63:5821-5828
7. O'Brien CA, Pollett A, Gallinger S, Dick JE 2006 A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 445:106-110
8. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA 2007 Melanoma contains CD133 and ABCG2 positive cells with enhanced tumorigenic potential. Eur J Cancer 43: 935-46
9. Takano T, Amino N 2005 Fetal cell carcinogenesis: A new hypothesis for better understanding of thyroid carcinoma. Thyroid 15:432-438
10. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals crosscontamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341
11. Alison MR, Lin WR, Lim SM, Nicholson LJ 2012 Cancer stem cells: In the line of fire. Cancer Treat Rev 38:589-598
12. Pellegriti G, De Vathaire F, Scollo C, Attard M, Giordano C, Arena S, Dardanoni G, Frasca F, Malandrino P, Vermiglio F, Previtera DM, D'Azzò G, Trimarchi F, Vigneri R 2009 Papillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst 101:1575-1583
13. World Health Organization 2004 Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. First edition. IARC Press, Lyon
14. Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, Pizzolanti G, Galluzzo A, Giordano C 2008 In vitro identification and characterization of CD133pos cancer stem-like cell in anaplastic carcinoma cell lines. PLoS One 3(10):e3544
15. Reya T, Morrison SJ, Clarke MF, Weissman IL 2001 Stem cells, cancer, and cancer stem cells. Nature 414:105-111
16. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S 2007 Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872
17. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA 2007 Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917- 1920
18. Patnaik MM, Tefferi A, Pardanani A 2007 Kit: Molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets 7:492- 503
19. Rege TA, Hagood JS 2006 Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 20:1045- 1054
20. Tokuyama S, Saito S, Takahashi T, Ohyama C, Ito A, Kanto S, Satoh M, Hoshi S, Endoh M, Arai Y 2003 Immunostaining of stage-specific embryonic antigen-4 in intratubular germ cell neoplasia unclassified and in testicular germ-cell tumours. Oncol Rep 10:1097-1104
21. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, de Munain AL, Sampron N, Aramburu A, Tejada-Solís S, Vicente C, Odero MD, Bandrés E, García-Foncillas J, Idoate MA, Lang FF, Fueyo J, Gomez-Manzano C 2011 Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 6:e26740
22. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G 2009 SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27:40-48
23. Güre AO, Stockert E, Scanlan MJ, Keresztes RS, Ja? ger D, Altorki NK, Old LJ, Chen YT 2000 Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 97:4188-4203
24. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez- Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J 2007 Sox2: A possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 20:474-481
25. Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, Okochi H, Okuda A, Matoba R, Sharov AA, Ko MS, Niwa H 2007 Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol. 9:625-635
26. Gu GY, Yuan JL, Wills M, Kasper S 2007 Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67:4807-4815
27. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF 2008 Positive correlations of Oct4 and Nanog in oral cancer stem-like cells and highgrade oral squamous cell carcinoma. Clin Cancer Res 14: 4085-4095
28. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, Robson P 2005 Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem 280:24731-24737
29. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, Markowitz D, Reisfeld RA, Luo Y 2011 Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer 104:1931
30. Ceckova M, Vackova Z, Radilova H, Libra A, Buncek M, Staud F 2008 Effect of ABCG2 on cytotoxicity of platinum drugs: Interference of EGFP. Toxicol In Vitro 22:1846-1852
31. Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV 2008 Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer 98:1515-1524
32. Zheng X, Cui D, Xu S, Brabant G, Derwahl M 2010 Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: Characterization of resistant cells. Int J Oncol 37:307-315
33. Singh S, Trevino JG, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP 2012 EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 11:73
34. Lin F, Lin P, Zhao D, Chen Y, Xiao L, Qin W, Li D, Chen H, Zhao B, Zou H, Zheng X, Yu X 2012 Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif 45:207-216
35. Prasmickaite L, Engesæter BØ, Skrbo N, Hellenes T, Kristian A, Nina K, Oliver NK, Suo Z, Mælandsmo GM 2010 Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One 5:e10731
36. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Jinsong Liu J 2009 ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 22:817-823
37. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ 2011 Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71:3991- 4001
38. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W 2012 Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 130:29-39
39. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G 2007 ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567
40. Jelski W, Chrostek L, Szmitkowski M 2007 The activity of class I, II, III, IV of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in pancreatic cancer. Pancreas 35:142-146
41. Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, Bonnet D 2005 Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 23:752-760
42. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS 2009 Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 178:48-55
43. Taubert I, Saffrich R, Zepeda-Moreno A, Hellwig I, Eckstein V, Bruckner T, Ho AD, Wuchter P 2011 Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. Cytotherapy 13:459-466
44. Klonisch T, Hoang-Vu C, Hombach-Klonisch S 2009 Thyroid stem cell and cancer. Thyroid 19:1303-1315